Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE: Potassium normalization regimen including sodium zirconium cyclosilicate in urgent hyperkalemia
2017-003955-50Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperkalemia comparing Sodium zirconium cyclosilicate arm with Placebo arm (2 arms). Primary endpoint: Mean absolute change in serum potassium at 4 hours. Started Nov 2017; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2017-003955-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003955-50.